PMID- 35289243
OWN - NLM
STAT- MEDLINE
DCOM- 20220524
LR  - 20230317
IS  - 1551-4005 (Electronic)
IS  - 1538-4101 (Print)
IS  - 1551-4005 (Linking)
VI  - 21
IP  - 12
DP  - 2022 Jun
TI  - CircCDR1 sponges miR-1290 to regulate cell proliferation, migration, invasion, 
      and apoptosis in esophageal squamous cell cancer.
PG  - 1316-1334
LID - 10.1080/15384101.2022.2050645 [doi]
AB  - Since circCDR1 was abnormally expressed in esophageal squamous cell cancer 
      (ESCC), the current study explored whether circCDR1 affected ESCC. Detailedly, 
      circCDR1 expression in ESCC and linear isoform and stability of circCDR1 were 
      detected by RT-qPCR. The location of circCDR1 was detected by fluorescence in 
      situ hybridization (FISH). After transfection, the cell biological functions were 
      detected by wound-healing, CCK-8, colony formation, and flow cytometry assays. 
      The target of circCDR1 was predicted by bioinformatics, FISH, RNA pull-down, and 
      dual-luciferase reporter assays. The correlation between circCDR1 and miR-1290 
      was analyzed by Pearson's correlation analysis. A subcutaneous-xenotransplant 
      tumor model in BALB/c nude mice was established and the levels of circCDR1, 
      miR-1290, and apoptosis/metastasis/proliferation-related factors in the cancer 
      cells and tissues were detected by immunohistochemical analysis, western blot, or 
      RT-qPCR. As a result, circCDR1 was low-expressed in ESCC tissues and cells, while 
      miR-1290 was high-expressed. CircCDR1 was regulated and was negatively correlated 
      with miR-1290. CircCDR1, located in cytoplasm, inhibited the viability, 
      proliferation, migration, and invasion of the cancer cells and the expressions of 
      Bcl-2, N-cadherin, and Vimentin, but enhanced cell apoptosis and the expressions 
      of C caspase-3, Bax, E-cadherin, IGFBP4, LHX6 and NFIX. In vivo, circCDR1 
      promoted xenotransplanted tumor weight and volume, and the expressions of C 
      caspase-3 and Bax yet suppressed the levels of Bcl-2, miR-1290, and Ki-67 in 
      tumor tissues. The effects of circCDR1 on both cancer cells and tissues were 
      opposite to and reversed by miR-1290 mimic. Collectively, circCDR1 sponged 
      miR-1290 to regulate the progression of ESCC both in vitro and in vivo.
FAU - Fang, Yong
AU  - Fang Y
AD  - Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, 
      China.
FAU - Yin, Jun
AU  - Yin J
AD  - Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, 
      China.
FAU - Shen, Yaxing
AU  - Shen Y
AD  - Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, 
      China.
FAU - Wang, Hao
AU  - Wang H
AD  - Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, 
      China.
FAU - Tang, Han
AU  - Tang H
AD  - Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, 
      China.
FAU - Chen, Xiaosang
AU  - Chen X
AD  - Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20220315
PL  - United States
TA  - Cell Cycle
JT  - Cell cycle (Georgetown, Tex.)
JID - 101137841
RN  - 0 (MicroRNAs)
RN  - 0 (NFI Transcription Factors)
RN  - 0 (Nfix protein, mouse)
RN  - 0 (bcl-2-Associated X Protein)
RN  - EC 3.4.22.- (Caspase 3)
SB  - IM
MH  - Animals
MH  - Apoptosis/genetics
MH  - *Carcinoma, Squamous Cell/genetics
MH  - Caspase 3/metabolism
MH  - Cell Line, Tumor
MH  - Cell Movement/genetics
MH  - Cell Proliferation/genetics
MH  - Epithelial Cells/metabolism
MH  - *Esophageal Neoplasms/metabolism
MH  - *Esophageal Squamous Cell Carcinoma/metabolism
MH  - Gene Expression Regulation, Neoplastic
MH  - In Situ Hybridization, Fluorescence
MH  - Mice
MH  - Mice, Nude
MH  - *MicroRNAs/genetics/metabolism
MH  - NFI Transcription Factors
MH  - Neoplasm Invasiveness/genetics
MH  - bcl-2-Associated X Protein/metabolism
PMC - PMC9132397
OTO - NOTNLM
OT  - ESCC
OT  - circCDR1
OT  - growth
OT  - miR-1290
OT  - xenotransplant tumor
COIS- No potential conflict of interest was reported by the author(s).
EDAT- 2022/03/16 06:00
MHDA- 2022/05/25 06:00
PMCR- 2023/03/15
CRDT- 2022/03/15 08:42
PHST- 2022/03/16 06:00 [pubmed]
PHST- 2022/05/25 06:00 [medline]
PHST- 2022/03/15 08:42 [entrez]
PHST- 2023/03/15 00:00 [pmc-release]
AID - 2050645 [pii]
AID - 10.1080/15384101.2022.2050645 [doi]
PST - ppublish
SO  - Cell Cycle. 2022 Jun;21(12):1316-1334. doi: 10.1080/15384101.2022.2050645. Epub 
      2022 Mar 15.